Novel risk factors and markers for coronary disease

Advances in Internal Medicine

Volumn 45, Issue , 2000, Pages 391-418

  Ridker, Paul M ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; FIBRINOGEN; HOMOCYSTEINE; LIPOPROTEIN A;

BLOOD; CORONARY ARTERY DISEASE; FIBRINOLYSIS; HUMAN; HYPERHOMOCYSTEINEMIA; REVIEW; RISK FACTOR; THROMBOPHILIA; VASCULITIS;

BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CORONARY DISEASE; FIBRINOGEN; FIBRINOLYSIS; HOMOCYSTEINE; HUMANS; HYPERHOMOCYSTEINEMIA; LIPOPROTEIN(A); RISK FACTORS; THROMBOPHILIA; VASCULITIS;

EID: 0033630648     PISSN: 00652822     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (147)

1. Ridker PM: Evaluating novel cardiovascular risk factors: Can we better predict heart attacks? Ann Intern Med 130:933-937, 1999.
2. Graver SA, Coupal L, Hu XP: Identifying adults at increased risk of coronary disease. How well do the current cholesterol guidelines work? JAMA 274:801-806, 1995.
3. Ridker PM: Fibrinolytic and inflammatory markers for arterial occlusion: The evolving epidemiology of thrombosis and hemostasis. Thromb Haemost 78:53-59, 1997.
4. Cambien F: Genetic prediction of myocardial infarction. Blood Coagul Fibrinolysis 10:23S-24S, 1999.
5. Tate JR, Rifai N, Berg K, et al: International Federation of Clinical Chemistry standardization project for the measurement of lipoprotein(a). Phase 1. Evaluation of the analytical performance of lipoprotein(a) assay systems and commercial calibrators. Clin Chem 44:1629-1640, 1998.
6. Angleton P, Chandler WL, Schmer G: Diurnal variation of tissue-type plasminogen activator and its rapid inhibition. Circulation 79:101-106, 1989.
7. Shipchandler MT, Moore EG: Rapid, fully automated measurement of plasma homocyst(e)ine with the Abbott IMx Analyzer. Clin Chem 41:991-995, 1995.
8. Ledue T, Weiner D, Sipe J, et al: Analytical evaluation of particle-enhanced immunonephelometric assays for C-reactive protein, serum amyloid A and mannose-binding protein in human serum. Ann Clin Biochem 35:745-53, 1998.
9. Detrano RC, Wong ND, Doherty TM, et al: Coronary calcium does not accurately predict near-term future coronary events in high-risk adults. Circulation 99:2633-2638, 1999.
10. Heinrich J, Balleisen L, Schulte H, et al: Fibrinogen and factor VII in the prediction of coronary risk: Results from the PROCAM study in healthy men. Arterioscler Thromb Vasc Biol 14:54-59, 1994.
11. Ridker PM, Glynn RJ, Hennekens CH: C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction. Circulation 97:2007-2011, 1998.
12. Pitt B, Rubenfire M: Risk stratification for detection of preclinical coronary artery disease. Circulation 99:2610-2612, 1999.
13. Malinow MR, Duell PB, Hess DL, et al: Reduction of plasma homocysteine levels by breakfast cereal fortified with folic acid in patients with coronary heart disease. N Engl J Med 338:1009-1015, 1998.
14. Jacques PF, Selhub J, Bostom AG, et al: The effect of folic acid fortification on plasma folate and total homocysteine concentrations. N Engl J Med 340:1449-1454, 1999.
15. Ridker PM, Rifai N, Pfeffer M, et al: Long-term effects of pravastatin plasma concentration of C-reactive protein. Circulation 100:230-235, 1999.
16. Ridker PM, Stampfer MJ: Assessment of genetic markers for coronary thrombosis: Promise and precaution. Lancet 353:687-688, 1999.
17. McLean JW, Tomlinson JE, Kuang WJ, et al: cDNA sequence of human apolipoprotein(a) is homologous to plasminogen. Nature 330:132-137, 1987.
18. Hajar KA, Gavish D, Breslow JL, et al: Lipoprotein(a) modulation of endothelial cell surface fibrinolysis and its potential role in atherosclerosis. Nature 339:303-305, 1989.
19. Harpel PC, Gordon BR, Parker TS: Plasmin catalyzes binding of lipoprotein(a) to immobilized fibrinogen and fibrin. Proc Natl Acad Sci U S A 86:3847-3851, 1989.
20. Loscalzo J, Weinfeld M, Fless GM, et al: Lipoprotein(a), fibrin-binding, and plasminogen activation. Arteriosclerosis 10:240-245, 1990.
21. Gushing GL, Gaubatz JW, Nava ML, et al: Quantification and localization of apolipoprotein(a) and B in coronary bypass grafts resected at reoperation. Arteriosclerosis 9:593-603, 1989.
22. Simon DI, Ezratty AM, Loscalzo J: Lipoprotein(a) and atherothrombosis. Curr Opin Cardiol 8:814-820, 1993.
23. Dangas G, Mehran R, Harpel PC, et al: Lipoprotein(a) and inflammation in human coronary atheroma: Association with the severity of clinical presentation. J Am Coll Cardiol 32:2035-2042, 1998.
24. Poon M, Zhang X, Dunsky KG, et al: Apolipoprotein(a) induces monocyte chemotactic activity in human vascular endathelial cells. Circulation 96:2514-2519, 1997.
25. Ridker PM, Hennekens CH, Stampfer MJ: A prospective study of lipoprotein(a) and the risk of myocardial infarction. JAMA 270:2195-2199, 1993.
26. Ridker PM, Stampfer MJ, Hennekens CH: Plasma concentration of lipoprotein(a) and the risk of future stroke. JAMA 273:1269-1273, 1995.
27. Jauhiainen M, Koskinen P, Ehnholm C et al: Lipoprotein(a) and coronary heart disease risk: A nested case-control study of the Helsinki Heart Study participants. Atherosclerosis 89:59-67, 1991.
28. Cantin B, Gagnon F, Moorjani S, et al: Is lipoprotein(a) an independent risk factor for ischemic heart disease in men? The Quebec Cardiovascular Study. J Am Coll Cordial 31:519-525, 1998.
29. Schaefer EJ, Lamon-Fava S, Jenner JL, et al: Lipoprotein(a) levels and risk of coronary heart disease in men. The Lipid Research Clinics Coronary Primary Prevention Trial. JAMA 271:999-1003, 1994.
30. Cremer P, Nagel D, Labrot B, et al: Lipoprotein Lp(a) as predictor of myocardial infarction in comparison to fibrinogen, LDL cholesterol and other risk factors: Results from the prospective Gottingen Risk Incidence and Prevalence Study (GRIPS). Eur J Clin Invest 24:444-453, 1994.
31. Wald NJ, Law M, Watt HC, et al: Apolipoproteins and ischaemic heart disease: implications for screening. Lancet 43:75-79, 1994.
32. Wild SH, Fortmann SP, Marcovina SM: A prospective case control study of lipoprotein(a) levels and apo(a) size and risk of coronary heart disease in Stanford five-city project participants. Arterioscler Thromb Vasc Biol 17:239-245, 1997.
33. Bostom AG, Gagnon DR, Cupples A, et al: A prospective investigation of elevated lipoprotein(a) detected by electrophoresis and cardiovascular disease in women: The Framingham Heart Study. Circulation 90:1688-1695, 1994.
34. Nguyen TT, Ellefson RD, Hodge DO, et al: Predictive value of electrophoretically detected lipoprotein(a) for coronary heart disease and cerebrovascular disease in a community-based cohort of 9936 men and women. Circulation 96:1390-1397, 1997.
35. Ridker PM: An epidemiologic reassessment of lipoprotein(a) and atherothrombotic risk. Trends Cardiovasc Med 5:225-229, 1995.
36. Weiss SR, Bachorik PS, Becker LC, et al: Lipoprotein(a) and coronary heart disease risk factors in a racially mixed population: The Johns Hopkins sibling study. Ethn Dis 8:60-72, 1998.
37. Moliterno DJ, Jokinen EV, Miserez AR, et al: No association between plasma lipoprotein(a) concentrations and the presence or absence of coronary atherosclerosis in African-Americans. Arterioscler Thromb Vasc Biol 15:850-855, 1995.
38. Sunayama S, Daida H, Mokuno H, et al: Lack of increased coronary atherosclerotic risk due to elevated lipoprotein(a) in women 55 years of age. Circulation 94:1263-1268, 1996.
39. Orth-Gomér K, Mittleman MA, Schenck-Gustafsson K, et al: Lipoprotein(a) as a determinant of coronary heart disease in young women. Circulation 95:329-334, 1997.
40. Maher VM, Brown BG, Marcovina SM, et al: Effects of lowering elevated LDL cholesterol on the cardiovascular risk of lipoprotein(a). JAMA 274:1771-1774, 1995.
41. Marcovina SM, Albers JJ, Gabel B, et al: Effect of the number of apo(a) kringle 4 domains on the immunochemical measurements of lipoprotein(a). Clin Chem 41:246-255, 1995.
42. Fortmann SP, Marcovina SM: Lipoprotein(a), a clinically elusive lipoprotein particle. Circulation 95:295-296, 1997.
43. McCully KS: Vascular pathology of homocysteinemia: Implications for the pathogenesis of arteriosclerosis. Am J Pathol 56:111-128, 1969.
44. Welch GN, Loscalzo J: Mechanisms of disease: Homocysteine and atherothrombosis. N Engl J Med 338:1042-1050, 1998.
45. Tsai J, Perrella MA, Yoshizumi M, et al: Promotion of vascular smooth muscle cell growth by homocysteine: A link to atherosclerosis. Proc Natl Acad Sci U S A 91:6369-6373, 1994.
46. Stamler JS, Osborne JA, Jaraki O, et al: Adverse vascular effects of homocysteine are modulated by endothelium-derived relaxing factor and related oxides of nitrogen. J Clin Invest 91:308-318, 1993.
47. Peterson JC, Spence JD: Vitamins and progression of atherosclerosis in hyperhomocysteinemia. Lancet 351:263, 1998.
48. Chambers JC, McGregor A, Jean-Marie J, et al: Acute hyperhomocysteinemia and endothelial dysfunction. Lancet 351:36-37, 1998.
49. Selhub J, Jacques PE, Wilson PW, et al: Vitamin status and intake as primary determinants of homocysteinemia in an elderly population. JAMA 270:2693-2698, 1993.
50. Rimm EB, Willett WC, Hu FB, et al: Folate and vitamin B6 from diet and supplements in relation to risk of coronary heart disease among women. JAMA 279:359-364, 1998.
51. Boushey CJ, Beresford SAA, Omenn GS, et al: A quantitative assessment of plasma homocysteine as a risk factor for vascular disease: Probable benefits of increasing folic acid intakes. JAMA 274:1049-1057, 1995.
52. Malinow MR, Bostom AG, Krauss RM: Homocyst(e)ine, diet, and cardiovascular diseases: A statement for healthcare professionals from the Nutrition Committee, American Heart Association. Circulation 99:178-182, 1999.
53. Egerton W, Silberberg J, Crooks R, et al: Serial measures of plasma homocysteine after acute myocardial infarction. Am J Cardiol 77:759-761, 1996.
54. Lindgren A, Brattstrom L, Norrving B, et al: Plasma homocysteine in the acute and convalescent phases after stroke. Stroke 26:795-800, 1995.
55. Evans RW, Shaten J, Hempel JD, et al: Homocysteine and risk of cardiovascular disease in the Multiple Risk Factor Intervention Trial. Arterioscler Thromb Vasc Biol 17:1947-1953, 1997.
56. Alfthan G, Pekkanen J, Juahianen M, et al: Relation of serum homocysteine and lipoprotein(a) concentrations to atherosclerotic disease in a prospective Finnish population based study. Atherosclerosis 106:9-19, 1994.
57. Stampfer MJ, Malinow MR, Willett WC, et al: A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians. JAMA 268:877-881, 1992.
58. Folsom AR, Nieto FJ, McGovern PG, et al: Prospective study of coronary heart disease incidence in relation to fasting total homocysteine, related genetic polymorphisms, and B vitamins. Circulation 98:204-210, 1998.
59. Arnesen E, Refsum H, Bonaa KH, et al: Serum total homocysteine and coronary heart disease. Int J Epidemiol 24:704-709, 1995.
60. Nygard O, Noidrehaug JE, Refsum H, et al: Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med 337:230-236, 1997.
61. Wald NJ, Watt HC, Law MR, et al: Homocysteine and ischemic heart disease: Results of a prospective study with implications regarding prevention. Arch Intern Med 158:862-867, 1998.
62. Bostom AG, Silbershatz H, Rosenberg IH, et al: Nonfasting plasma total homocysteine levels and all-cause and cardiovascular disease mortality in elderly Framingham men and women. Arch Intern Med 159:1077-1080, 1999.
63. Ridker PM, Manson JE, Buring JE, et al: Homocysteine and risk of cardiovascular disease among postmenopausal women. JAMA 281:1817-1821, 1999.
64. Werler MM, Shapiro S, Mitchell AA: Periconceptional folic acid exposure and risk of occurrent neural tube defects. JAMA 269:1257-1261, 1993.
65. Bostom AG, Lathrop L: Hyperhomocysteinemia in end-stage renal disease: Prevalence, etiology, and potential relationship to arteriosclerotic outcomes. Kidney Int 52:10-20, 1997.
66. Nedrebo BG, Ericsson UB, Nygard O, et al: Plasma total homocysteine levels in hypothyroid and hyperthyroid patients. Metabolism 47:89-93, 1998.
67. Brattstrom L, Wilcken DEL, Ohrvik J, et al: Common methylenetetrahydrofolate reductase gene mutation leads to hyperhomocysteinemia but not to vascular disease. The result of a meta-analysis. Circulation 98:2520-2526, 1998.
68. Collen D, Lijnen HR: Basic and clinical aspects of fibrinolysis and thrombolysis. Blood 78:3114-3124, 1991.
69. Reilly CF, Fujita T, Hutzelmann JE, et al: Plasminogen activator inhibitor 1 suppresses endogenous fibrinolysis in a canine model of pulmonary embolism. Circulation 84:287-292, 1991.
70. Farrehi PM, Ozaki CK, Carmeliet P, et al: Regulation of arterial thrombolysis by plasminogen activator inhibitor-1 in mice. Circulation 97:1002-1008, 1998.
71. Hamsten A, Walldius G, Szamosi A, et al: Plasminogen activator inhibitor in plasma: Risk factor for recurrent myocardial infarction. Lancet 2:3-9, 1987.
72. Jansson JH, Olofsson BO, Nilsson TK: Predictive value of tissue plasminogen activator mass concentration on long term mortality in patients with coronary artery disease: A seven year follow-up. Circulation 88:2030-2034, 1993.
73. Ridker PM, Vaughan DE, Stampfer MJ, et al: Endogenous tissue-type plasminogen activator and risk of myocardial infarction. Lancet 341:1165-1168, 1993.
74. Ridker PM, Hennekens CH, Stampfer MJ, et al: Prospective study of endogenous tissue plasminogen activator and risk of stroke. Lancet 343:940-43, 1994.
75. Ridker PM, Hennekens CH, Cerskus A, et al: Plasma concentration of cross linked fibrin degradation product (D-dimer) and the risk of future myocardial infarction among apparently healthy men. Circulation 90:2236-2240, 1994.
76. Meade TW, Ruddock V, Stirling Y, et al: Fibrinolytic activity, clotting factors, and long-term incidence of ischaemic heart disease in the Northwick Park Heart Study. Lancet 342:1076-1079, 1993.
77. Fowkes FGR, Lowe GDO, Housley E, et al: Cross-linked fibrin degradation products, progression of peripheral arterial disease, and risk of coronary heart disease. Lancet 342:84-86, 1993.
78. Thompson SG, for the European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group: Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. N Engl J Med 332:635-641, 1995.
79. Juhan-Vague I, on behalf of the ECAT Study Group: Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. Circulation 94:2057-2063, 1996.
80. Lowe GDO, Yarnell JWG, Sweetnam PM, et al: Fibrin D-dimer, tissue plasminogen activator, plasminogen activator inhibitor, and the risk of major ischaemic heart disease in the Caerphilly Study. Thromb Haemost 79:129-133, 1998.
81. Thogersen AM, Jansson JH, Boman K, et al: High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women: Evidence for the fibrinolytic system as an independent primary risk factor. Circulation 98:2241-2247, 1998.
82. Juhan-Vague I, Thompson SG, Jespersen J: Involvement of the hemostatic system in the insulin resistance syndrome. A study of 1500 patients with angina pectoris. Arterioscler Thromb Vasc Biol 13:1865-1873, 1993.
83. Potter van Loon BJ, Kluft C, Radder JK, et al: The cardiovascular risk factor plasminogen activator inhibitor type 1 is related to insulin resistance. Metabolism 42:945-949, 1993.
84. Shimomura I, Funahashi T, Takahashi M, et al: Enhanced expression of PAI-I in visceral fat: Possible contributor to vascular disease in obesity. Nat Med 2:800-803, 1996.
85. Alessi MC, Peiretti F, Morange P, et al: Production of plasminogen activator inhibitor 1 by human adipose tissue. Possible link between visceral fat accumulation and vascular disease. Diabetes 46:860-867, 1997.
86. Lundgren CH, Brown SL, Nordt TD, et al: Elaboration of type 1 plasminogen activator inhibitor from adipocytes. A potential pathogenetic link between obesity and cardiovascular disease. Circulation 93:106-110, 1996.
87. Desprès JP, Lamarche B, Mauriège P, et al: Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Eng J Med 334:952-957, 1996.
88. Ridker PM, Gaboury CL, Conlin PR, et al: Stimulation of plasminogen activator inhibitor in vivo by infusion of angiotensin II: Evidence of a potential interaction between the renin angiotensin system and fibrinolytic function. Circulation 87:1969-1973, 1993.
89. Wright RA, Flapan AD, Alberti KGMM, et al: Effects of captopril therapy on endogenous fibrinolysis in men with recent, uncomplicated myocardial infarction. J Am Coll Cardiol 24:67-73, 1994.
90. Vaughan DE, on behalf of the HEART study investigators: Effects of remipril on plasma fibrinolytic balance in patients with acute anterior myocardial infarction. Circulation 96:442-447, 1997.
91. Dawson SJ, Wiman B, Hamsten A, et al: The two allele sequences of a common polymorphism in the promotor of the plasminogen activator inhibitor (PAI-1) gene respond differently to interleukin-1 in HepG2 cells. J Biol Chem 268:10739-10745, 1993.
92. Ye S, Green FR, Scarabin PY, et al: The 4G/5G genetic polymorphism in the promotor of the plasminogen activator inhibitor-1 (PAI-1) gene is associated with differences in plasma PAI-1 activity but not with risk of myocardial infarction in the ECTIM study. Thromb Haemost 74:837-841, 1995.
93. Eriksson P, Kallin B, van't Hooft FM, et al: Allele-specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction. Proc Natl Acad Sci U S A 92:1851-1855, 1995.
94. Ridker PM, Hennekens CH, Lindpaintner K, et al: Arterial and venous thrombosis is not associated with the 4G/5G polymorphism in the promotor of the plasminogen activator inhibitor (PAI-1) gene in a large cohort of US men. Circulation 95:59-62, 1997.
95. van der Bom JG, de Knijff P, Haverkate F, et al: Tissue plasminogen activator and risk of myocardial infarction. Circulation 95:2623-2627, 1997.
96. Ridker PM, Baker MT, Hennekens CH, et al: Alu-repeat polymorphism in the gene coding for tissue-type plasminogen activator (t-PA) and risks of myocardial infarction among middle-aged men. Arterioscler Thromb Vasc Biol 17:1687-1690, 1997.
97. Henry M, Tregouet DA, Alessi MC, et al: Metabolic determinants are much more important than genetic polymorphisms in determining the PAI-1 activity and antigen plasma concentrations: A family study with part of the Stanislas cohort. Arterioscler Thromb Vasc Biol 18:84-91, 1998.
98. Ernst E, Resch KL: Fibrinogen as a cardiovascular risk factor: A meta-analysis and review of the literature. Ann Intern Med 118:956-963, 1993.
99. Smith EB: Fibrinogen, fibrin and fibrin degradation products in relation to atherosclerosis. Clin Haematol 15:355-370, 1986.
100. Wilhelmsen L, Svärdsudd K, Korsan-Bengtsen K, et al: Fibrinogen as a risk factor for stroke and myocardial infarction. N Engl J Med 311:501-505, 1984.
101. Meade TW, Mellows S, Brozovic M, et al: Haemostatic function and ischemic heart disease: Principal results of the Northwick Park Heart Study. Lancet 2:533-537, 1986.
102. Kannel WB, Wolf PA, Castelli WP, et al: Fibrinogen and risk of cardiovascular disease. The Framingham Study. JAMA 258:1183-1186, 1987.
103. Heinrich J, Balleisen L, Schulte H, et al: Fibrinogen and factor VII in the prediction of coronary risk: Results from the PROCAM study in healthy men. Arterioscler Thromb Vasc Biol 14:54-59, 1994.
104. Yarnell JWG, Baker IA, Sweetnam PM, et al: Fibrinogen, viscosity, and white blood cell count are major risk factors for ischemic heart disease. The Caerphilly and Speedwell Collaborative Heart Disease Studies. Circulation 83:836-844, 1991.
105. Cremer P, Nagel D, Labrot B, et al: Lipoprotein Lp(a) as predictor of myocardial infarction in comparison to fibrinogen, LDL cholesterol and other risk factors: Results from the prospective Gottingen Risk Incidence and Prevalence Study (GRIPS). Eur J Clin Invest 24:444-453, 1994.
106. Ma J, Hennekens CH, Ridker PM, et al: A prospective study of fibrinogen and risk of myocardial infarction in the Physicians' Health Study. J Am Coll Cardiol 33:1347-1352, 1999.
107. Wu KK, Folsom AR, Heiss G, et al: Association of coagulation factors and inhibitors with carotid artery atherosclerosis: Early results of the Atherosclerosis Risk in Communities (ARIC) Study. Ann Epidemiol 2:471-480, 1992.
108. Tracy RP, Bovill EG, Yanez D, et al: Fibrinogen and factor VIII, but not factor VII, are associated with measures of subclinical cardiovascular disease in the elderly. Results from the Cardiovascular Health Study. Arterioscler Thromb Vasc Biol 15:1269-1279, 1995.
109. Kannel WB, D'Agostino RB, Belanger AJ: Fibrinogen, cigarette smoking, and risk of cardiovascular disease: Insights from the Framingham Study. Am Heart J 113:1006-1010, 1987.
110. Meade TW, Imeson J, Stirling Y: Effects of changes in smoking and other characteristics on clotting factors and the risk of ischaemic heart disease. Lancet 2:986-988, 1987.
111. Nabulsi AA, for the Atherosclerosis Risk in Communities Study Investigators: Association of hormone replacement therapy with various cardiovascular risk factors in postmenopausal women. N Engl J Med 328:1069-1075, 1993.
112. The Writing Group for the PEPI Trial: Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA 273:199-208, 1995.
113. Ernst E: Lowering the plasma fibrinogen with drugs. Clin Pharmacist 11:968-971, 1992.
114. Goldbout U, Behar S, Reicher-Reiss H, et al: Rationale and design of a secondary prevention trial of increasing serum HDL cholesterol and reducing triglycerides after myocardial infarction in patients with clinically manifest atherosclerotic heart disease (The Bezafibrate Infarction Prevention Study). Am J Cardiol 71:909-915, 1993.
115. Behar S, for the BIP Study Group: Lowering fibrinogen levels: Clinical update. Blood Coagul Fibrinolysis 10:41S-43S, 1999.
116. Ross R: Atherosclerosis - An inflammatory disease. N Engl J Med 340:115-126, 1999.
117. Libby P: Molecular bases of the acute coronary syndromes. Circulation 91:2844-2850, 1995.
118. Moreno PR, Falk E, Palacios IF, et al: Macrophage infiltration in acute coronary syndromes. Implications for plaque rupture. Circulation 90:775-778, 1994.
119. van der Wal AC, Becker AE, van dor Loos CM, et al: Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology. Circulation 89:36-44, 1994.
120. Cybulsky MI, Gimbrone MA Jr: Endothelial expression of a mononuclear leukocyte adhesion molecule during atherogenesis. Science 251:788-791, 1991.
121. Mach F, Schonbeck U, Bonnefoy JY, et al: Activation of monocyte/macrophage functions related to acute atheroma complication by ligation of CD40: Induction of collagenase, stromelysin, and tissue factor. Circulation 96:396-399, 1997.
122. Lee RT, Libby P: The unstable atheroma. Arterioscler Thromb Vasc Biol 17:1859-1867, 1997.
123. Ridker PM, Haughie P: Prospective studies of C-reactive protein as a risk factor for cardiovascular disease. J Investig Med 46:391-395, 1998.
124. Ridker PM, Hennekens CH, Roitman-Johnson B, et al: Plasma concentration of soluble intercellular adhesion molecule 1 and risks of future myocardial infarction in apparently healthy men. Lancet 351:88-92, 1998.
125. Hwang S-J, Ballantyne CM, Sharrett AR, et al: Circulating adhesion molecules VCAM-1, ICAM-1, and E-selectin in carotid atherosclerosis and incident coronary heart disease cases. The Atherosclerosis Risk in Communities (ARIC) Study. Circulation 96:4219-4225, 1997.
126. Danesh J, Collins R, Appleby P, et al: Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: Meta-analyses of prospective studies. JAMA 279:1477-1482, 1998.
127. Harris TB, Ferrucci L, Tracy RP, et al: Associations of elevated interleukin-6 and C-reactive protein with mortality in the elderly. Am J Med 106:506-512, 1999.
128. Pepys MB, Baltz ML: Acute phase proteins with special reference to C-reactive protein and related proteins (pentaxins) and serum amyloid A protein. Adv Immunol 34:141-212, 1983.
129. Cermak J, Key NS, Bach RR, et al: C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor. Blood 82:513-520, 1993.
130. Wolbink GJ, Brouwer MC, Buysmann S, et al: C-reactive protein mediated activation of complement in vivo. Assessment by measuring circulating complement-C-reactive protein complexes. J Immunol 157:473-479, 1996.
131. Zouki C, Beauchamp M, Baron C, et al: Prevention of in vitro neutrophil adhesion to endothelial cells through shedding of L-selectin by C-reactive protein and peptides derived from C-reactive protein. J Clin Invest 100:522-529, 1997.
132. Ridker PM, Cushman M, Stampfer M, et al: Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 336:973-979, 1997.
133. Ridker PM, Cushman M, Stampfer MJ, et al: Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease. Circulation 97:425-428, 1998.
134. Ridker PM, Buring JE, Shih J, et al: Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation 98:731-733, 1998.
135. Tracy RP, Lemaitre RN, Psaty BM, et al: Relationship of C-reactive protein to risk of cardiovascular disease in the elderly. Results from the Cardiovascular Health Study and the Rural Health Promotion Project. Arterioscler Thromb Vasc Biol 17:1121-1127, 1997.
136. Kuller LH, for the MRFIT Research Group: Relationship of C-reactive protein and coronary heart disease in the MRFIT nested case-control study. Am J Epidemiol 144:537-547, 1996.
137. Koenig W, Sund M, Frolich M, et al: C-reactive protein, a sensitive marker for inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men. Results from the MONICA-Augsberg Cohort Study 1984-1992. Circulation 99:237-242, 1999.
138. Liuzzo G, Biasucci LM, Gallimore JR, et al: The prognostic value of C-reactive protein and serum amyloid A protein in severe unstable angina. N Engl J Med 331:417-424, 1994.
139. Haverkate F, for the European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group: Production of C-Reactive protein and risk of coronary events in stable and unstable angina. Lancet 349:462-466, 1997.
140. Morrow D, Rifai N, Antman E, et al: C-reactive protein is a potent predictor of mortality independently and in combination with troponin T in acute coronary syndromes. J Am Coll Cardiol 31:1460-1465, 1998.
141. Toss H, Lindahl B, Seigahn A, et al: Prognostic influence of fibrinogen and C-reactive protein levels in unstable coronary artery disease. FRISC Study Group. Circulation 96:4204-4210, 1997.
142. Ridker PM, for the Cholesterol and Recurrent Events (CARE) Investigators: Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Circulation 98:839-844, 1998.
143. Mendall MA, Patel P, Ballam L, et al: C reactive protein and its relation to cardiovascular risk factors: A population based cross sectional study. BMJ 312:1061-1065, 1996.
144. Cushman M, Meilahn EN, Psaty BM, et al: Hormone replacement therapy, inflammation, and hemostasis in elderly women. Arterioscler Thromb Vasc Biol 19:893-899, 1999.
145. Ridker PM, Hennekens CH, Rifai N, et al: Hormone replacement therapy and increased plasma concentration of C reactive protein. Circulation 100:713-716, 1999.
146. Wilkins J, Gallimore R, Moore E, et al: Rapid automated high sensitivity enzyme immunoassay of C-reactive protein. Clin Chem 44:1358-1361, 1998.
147. Stampfer MJ, Sacks FM, Salvini S, et al: A prospective study of cholesterol, apolipoproteins, and the risk of myocardial infarction. N Engl J Med 325:373-381, 1991.